FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Not Applicable

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Childhood Acute Myeloid Leukemia in Remission
Childhood Myelodysplastic Syndromes
de Novo Myelodysplastic Syndromes

Interventions: Drug: cyclophosphamide
Drug: busulfan
Drug: tacrolimus
Drug: methotrexate
Genetic: cytogenetic analysis
Other: flow cytometry
Other: pharmacological study
Other: pharmacogenomic studies
Procedure: peripheral blood stem cell transplantation
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2007-03-09

Last Posted Date: 2018-01-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 52

Registration Number: NCT00445744

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

Phase 2

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2007-02-22

Last Posted Date: 2009-03-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 43

Registration Number: NCT00438841

Locations: 🇺🇸
Oregon Health and Science University Cancer Institute, Portland, Oregon, United States
🇺🇸
Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs, California, United States
🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 7 locations

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Breast Cancer
Chronic Myeloproliferative Disorders
Gestational Trophoblastic Tumor
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Neuroblastoma

First Posted Date: 2006-12-13

Last Posted Date: 2010-05-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00410657

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant

Not Applicable

Completed

Conditions: Noncontiguous Stage II Mantle Cell Lymphoma
Noncontiguous Stage II Marginal Zone Lymphoma
Noncontiguous Stage II Small Lymphocytic Lymphoma
Previously Treated Childhood Rhabdomyosarcoma
Primary Myelofibrosis
Recurrent Adult Acute Myeloid Leukemia
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma

Interventions: Drug: lithium carbonate
Other: laboratory biomarker analysis

First Posted Date: 2006-12-07

Last Posted Date: 2017-03-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00408681

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Phase 2

Completed

Conditions: Refractory Anemia With Excess Blasts
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
de Novo Myelodysplastic Syndrome
Refractory Anemia
Refractory Anemia With Ring Sideroblasts
Polycythemia Vera
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Chronic Myelomonocytic Leukemia
Essential Thrombocythemia

Interventions: Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2006-11-10

Last Posted Date: 2020-01-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 77

Registration Number: NCT00397813

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸
Veterans Administration Center-Seattle, Seattle, Washington, United States

Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2006-09-21

Last Posted Date: 2011-11-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 12

Registration Number: NCT00378768

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

Phase 2

Terminated

Conditions: Severe Aplastic Anemia
Genetic Disorder
Immunodeficiency Syndrome

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Sirolimus
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2006-08-01

Last Posted Date: 2021-01-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00358657

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
The Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Cancer

First Posted Date: 2006-07-27

Last Posted Date: 2010-09-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00357084

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant

Phase 1

Terminated

Conditions: Aplastic Anemia

Interventions: Radiation: total-body irradiation
Drug: cyclophosphamide
Biological: anti-thymocyte globulin
Drug: cyclosporine
Procedure: umbilical cord blood transplantation
Drug: mycophenolate mofetil
Procedure: bone marrow aspiration
Genetic: DNA analysis
Biological: filgrastim

First Posted Date: 2006-07-20

Last Posted Date: 2011-01-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00354419

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2006-06-29

Last Posted Date: 2010-05-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00346359

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy